乳腺癌新辅助化疗研究现状
被引量:1
The present status of neoadjuvant chemotherapy on breast cancer
摘要
乳腺癌新辅助化疗日益受到重视 ,与常规辅助化疗相比具有诸多优势 ,现综述近年来新辅助化疗的研究现状和临床应用前景。
出处
《国外医学(肿瘤学分册)》
2003年第6期441-444,共4页
Foreign Medical Sciences (Cancer Section)
参考文献19
-
1Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer[J]. Br J Cancer, 2002, 86(7): 1041-1046.
-
2Rouzier R, Extra JM, Carton M, et al . Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery[J]. J Clin Oncol, 2001,19 (18): 3828-3835.
-
3Cance WG, Carey LA, Calvo BF, et al . Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival[J]. Ann Surg, 2002, 236(3):295-302.
-
4Braud AC, Levy E, Feuilhade F, et al . Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase Ⅱ study[J]. AmJ Clin Oncol, 2002, 25(3):303-307.
-
5Manriac L, Durand M, Avril A, et al . Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre[J]. Ann Oncol, 1991, 2(5):347-354.
-
6Soloil SM, Pierga JY, Asselain B, et al . Breast tumour response to primary chemotherapy predicts local and distant control as well as survival[J]. Eur J Cancer, 1995, 31A(12) :1969-1975.
-
7Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast eancer[J]. Ann Oncol, 1998, 9(11): 1179-1184.
-
8van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902[J]. J Clin Oncol, 2001, 19(22) :4224-4237.
-
9Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel[J]. J Clin Oncol, 2002, 20(6): 1456-1466.
-
10Therasse P, Mauriac L, Welnicka Jaskiewicz M, et al. Final results of a randomized phase Ⅲ trial comparing cyclophosphamide,epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study[J]. J Clin Oncol, 2003, 21(5):843-850.
同被引文献7
-
1刘宏军,沈丹华,刘鹏,王殊,曹迎明,周波,佟富中,杨德启,乔新民,张嘉庆.新辅助化疗后乳腺癌的临床病理学改变[J].中国妇产科临床杂志,2005,6(1):44-47. 被引量:11
-
2朱元喜,方志沂,马淑资.乳腺癌新辅助化疗不同方案疗效及安全性比较[J].中国肿瘤临床与康复,2001,8(3):18-20. 被引量:32
-
3杨德启,佟富中,曹迎明,刘鹏,周波,刘宏军,乔新民,张嘉庆.不同新辅助化疗方案治疗乳腺癌的临床观察[J].中华肿瘤杂志,2002,24(3):303-305. 被引量:24
-
4陈灿铭,沈坤炜,沈镇宙.可手术乳腺癌系统性辅助化疗[J].实用临床医药杂志,2003,7(2):107-111. 被引量:12
-
5崔树德.Her-2在新辅助化疗乳腺癌中的表达及预后意义[J].中国煤炭工业医学杂志,2003,6(11):1088-1089. 被引量:3
-
6佟富中,周波,杨德启,曹迎明,刘鹏,刘宏军,王殊,乔新民,张嘉庆.不同周期的新辅助化疗对乳腺癌疗效的影响[J].中华普通外科杂志,2004,19(4):205-207. 被引量:8
-
7吴秀萍,谢源福.局部晚期乳腺癌新辅助化疗48例初探并文献复习[J].临床医药实践,2004,13(6):436-438. 被引量:4
二级引证文献2
-
1魏树新,刘军,鲁明.化疗联合天芝草胶囊治疗乳腺癌术后的临床观察[J].中国基层医药,2010,17(17):2340-2341.
-
2车潇良,蔡媛,冯建丽,谭军霞,郑甦,江奎.乳腺癌新辅助化疗疗效及与激素受体相关性的临床观察[J].现代肿瘤医学,2012,20(2):304-306. 被引量:8
-
1马秋英.宫颈癌手术前治疗[J].华夏医学,2007,20(5):1145-1148. 被引量:6
-
2刘大文,王建,毛哲玉,赵亮.新辅助化学治疗联合手术治疗食管癌的临床疗效及对患者生活质量的影响[J].新乡医学院学报,2013,30(2):111-113. 被引量:5
-
3杨春燕,龙爱娥.新辅助化学治疗宫颈癌36例临床分析[J].中国肿瘤临床与康复,2008,15(3):232-234. 被引量:5
-
4姜伟,魏红,陈德福,袭超.新辅助化疗联合手术与单纯手术治疗食管癌的临床疗效分析[J].中国医药指南,2014,12(22):22-23. 被引量:5
-
5戴夕春.新辅助化疗TEC方案治疗晚期乳腺癌的疗效观察[J].中国医药导刊,2014,16(10):1330-1331. 被引量:1
-
6郭朝容.妊娠合并宫颈鳞状细胞癌患者的个性化护理一例[J].华西医学,2014,29(11):2199-2200. 被引量:1
-
7符勇,王国雄.Ⅲ期胃癌新辅助化学治疗[J].海南医学,2002,13(1):10-11.
-
8杨敬茂,赵钧生.新辅助化学治疗对非小细胞肺癌淋巴管生成及增殖活性的影响[J].中国保健营养(下半月),2013,0(5):1073-1073.
-
9张爱平,徐教瑜,刘子雄,缪劲,郭子璜,高岩.287例Ⅲ期非小细胞肺癌临床治疗效果分析[J].南京医科大学学报(自然科学版),2005,25(1):49-51.
-
10姜华,李玺,黄勇,邱万寿,刘瑞磊,吴珏堃,黄泽楠,刘仁斌.吉西他滨联合长春瑞滨用于乳腺癌二线新辅助化学治疗的观察[J].新医学,2012,43(9):631-634. 被引量:5